[CROI 2026] [Press release] Merck announces late-breaking data from three Phase 3 trials evaluating doravirine/islatravir, an investigational, once-daily, two-drug regimen for the treatment of adults living with HIV-1 at CROI 2026

Merck press release

Merck announced the presentation of results from three pivotal Phase 3 trials evaluating the investigational, once-daily, oral, two-drug regimen of doravirine/islatravir [DOR/ISL (100 mg/0.25 mg), (MK-8591A)] in adults with HIV-1. The findings were shared in late-breaking presentations at CROI 2026.

— DOR/ISL is the first non-INSTI, two-drug regimen to demonstrate non-inferiority and a similar safety profile at Week 48 to bictegravir/emtricitabine/tenofovir alafenamide in adults living with HIV-1 who had not previously received antiretroviral treatment (MK-8591A-053 trial)

— DOR/ISL maintained virologic suppression at Week 96 in adults with virologically suppressed HIV-1 who switched from other oral antiretroviral therapies, including bictegravir/emtricitabine/tenofovir alafenamide (MK-8591A-051 & MK-8591A-052 trials)

Read the full press release here.